China · Delayed Price · Currency is CNY Newland Pharmaceutical Statistics
Total Valuation
SHE:301277 has a market cap or net worth of CNY 4.76 billion. The enterprise value is 4.05 billion.
| Market Cap | 4.76B |
| Enterprise Value | 4.05B |
Important Dates
The next confirmed earnings date is Friday, March 20, 2026.
| Earnings Date | Mar 20, 2026 |
| Ex-Dividend Date | Apr 16, 2025 |
Share Statistics
SHE:301277 has 392.08 million shares outstanding. The number of shares has decreased by -0.88% in one year.
| Current Share Class | 392.08M |
| Shares Outstanding | 392.08M |
| Shares Change (YoY) | -0.88% |
| Shares Change (QoQ) | -1.91% |
| Owned by Insiders (%) | 63.76% |
| Owned by Institutions (%) | 0.72% |
| Float | 98.88M |
Valuation Ratios
The trailing PE ratio is 39.13.
| PE Ratio | 39.13 |
| Forward PE | n/a |
| PS Ratio | 7.07 |
| PB Ratio | 3.07 |
| P/TBV Ratio | 3.17 |
| P/FCF Ratio | 305.81 |
| P/OCF Ratio | 40.67 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 21.60, with an EV/FCF ratio of 260.19.
| EV / Earnings | 33.37 |
| EV / Sales | 6.02 |
| EV / EBITDA | 21.60 |
| EV / EBIT | 30.34 |
| EV / FCF | 260.19 |
Financial Position
The company has a current ratio of 6.26, with a Debt / Equity ratio of 0.00.
| Current Ratio | 6.26 |
| Quick Ratio | 5.81 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | 0.03 |
| Debt / FCF | 0.37 |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is 7.76% and return on invested capital (ROIC) is 14.46%.
| Return on Equity (ROE) | 7.76% |
| Return on Assets (ROA) | 4.64% |
| Return on Invested Capital (ROIC) | 14.46% |
| Return on Capital Employed (ROCE) | 8.29% |
| Weighted Average Cost of Capital (WACC) | 6.39% |
| Revenue Per Employee | 645,277 |
| Profits Per Employee | 116,361 |
| Employee Count | 1,042 |
| Asset Turnover | 0.37 |
| Inventory Turnover | 7.45 |
Taxes
In the past 12 months, SHE:301277 has paid 14.06 million in taxes.
| Income Tax | 14.06M |
| Effective Tax Rate | 10.48% |
Stock Price Statistics
The stock price has increased by +4.12% in the last 52 weeks. The beta is 0.39, so SHE:301277's price volatility has been lower than the market average.
| Beta (5Y) | 0.39 |
| 52-Week Price Change | +4.12% |
| 50-Day Moving Average | 12.50 |
| 200-Day Moving Average | 13.58 |
| Relative Strength Index (RSI) | 44.08 |
| Average Volume (20 Days) | 2,186,042 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, SHE:301277 had revenue of CNY 672.38 million and earned 121.25 million in profits. Earnings per share was 0.31.
| Revenue | 672.38M |
| Gross Profit | 234.74M |
| Operating Income | 133.36M |
| Pretax Income | 134.12M |
| Net Income | 121.25M |
| EBITDA | 186.35M |
| EBIT | 133.36M |
| Earnings Per Share (EPS) | 0.31 |
Balance Sheet
The company has 718.55 million in cash and 5.69 million in debt, with a net cash position of 712.86 million or 1.82 per share.
| Cash & Cash Equivalents | 718.55M |
| Total Debt | 5.69M |
| Net Cash | 712.86M |
| Net Cash Per Share | 1.82 |
| Equity (Book Value) | 1.55B |
| Book Value Per Share | 4.00 |
| Working Capital | 896.33M |
Cash Flow
In the last 12 months, operating cash flow was 116.94 million and capital expenditures -101.38 million, giving a free cash flow of 15.55 million.
| Operating Cash Flow | 116.94M |
| Capital Expenditures | -101.38M |
| Depreciation & Amortization | 52.99M |
| Net Borrowing | n/a |
| Free Cash Flow | 15.55M |
| FCF Per Share | 0.04 |
Margins
Gross margin is 34.91%, with operating and profit margins of 19.83% and 18.03%.
| Gross Margin | 34.91% |
| Operating Margin | 19.83% |
| Pretax Margin | 19.95% |
| Profit Margin | 18.03% |
| EBITDA Margin | 27.71% |
| EBIT Margin | 19.83% |
| FCF Margin | 2.31% |
Dividends & Yields
This stock pays an annual dividend of 0.29, which amounts to a dividend yield of 2.28%.
| Dividend Per Share | 0.29 |
| Dividend Yield | 2.28% |
| Dividend Growth (YoY) | 40.00% |
| Years of Dividend Growth | 3 |
| Payout Ratio | 92.39% |
| Buyback Yield | 0.88% |
| Shareholder Yield | 3.17% |
| Earnings Yield | 2.55% |
| FCF Yield | 0.33% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on April 16, 2025. It was a forward split with a ratio of 1.4.
| Last Split Date | Apr 16, 2025 |
| Split Type | Forward |
| Split Ratio | 1.4 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 3 |